Exscienta specialises in In silico drug discovery. This includes automated design of new compounds, using computational evolution.
Exscientia’s mission is to make safer, more sophisticated drugs available to all - more quickly and efficiently using AI drug discovery platforms. Exscientia generates their own data and combines the analytical power of AI with the creativity and expertise of their world-class scientists. This allows them to shorten the pre-clinical drug discovery stage and in turn, substantially accelerate the path to clinical testing, with the prospect of delivery of new treatments to patients worldwide.
The company has won numerous prizes for the founder and the business including the Queen’s Award for Enterprise Innovation, recognizing its pioneering work in the field of AI-driven drug discovery. In 2021, Exscientia was named the number 1 fastest growing pharma/biotech in the UK in the Alantra Pharma Fast 50.